Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
March 23, 2023 03:00 ET
|
Anaveon
BASEL, Switzerland, March 23, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for...
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 16, 2023 08:00 ET
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual Meeting
March 16, 2023 05:00 ET
|
Medigene AG
Martinsried/Munich, March 16, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell...
iOmx Therapeutics to Present Target Discovery Platform Myeloid iOTarg™ and New Data on SIK Checkpoint Inhibitor OMX-0407 at AACR 2023
March 15, 2023 10:30 ET
|
iOmx Therapeutics AG
Discovery of novel immune checkpoints in the tumor microenvironment with iOTarg™ screening platformPredictive biomarker signature for lead product candidate OMX-0407 MUNICH, Germany, March 15, 2023 ...
Theratechnologies présentera à AACR des données précliniques démontrant la synergie entre le TH1902 et l’immunothérapie anti-PD-L1 dans un modèle de tumeur froide
March 14, 2023 18:42 ET
|
Theratechnologies
Les données indiquent que le sudocétaxel zendusortide (TH1902) peut induire l’infiltration de lymphocyte dans les tumeurs et potentialiser l’immunothérapie au moyen d’agents anti-PD-L1 chez un modèle...
Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
March 14, 2023 18:42 ET
|
Theratechnologies
Data show that sudocetaxel zendusortide (TH1902) can induce tumor infiltrating lymphocytes and potentiate anti-PD-L1 immunotherapy in a melanoma mouse model Two other studies highlight activity of...
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
March 14, 2023 18:21 ET
|
Harpoon Therapeutics
Preclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®)...
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023
March 14, 2023 17:58 ET
|
Mablink
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023 In vivo antitumor efficacy with significant tumor growth inhibition in multiple...
Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting
March 14, 2023 17:32 ET
|
Kura Oncology, Inc.
– Presentations to highlight preclinical data supporting combination of FTIs with KRASG12C inhibitors and tyrosine kinase inhibitors – SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology,...
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
March 14, 2023 17:30 ET
|
ImCheck Therapeutics SAS
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR Marseille, France, March 14, 2023 – ImCheck Therapeutics...